ArticleAntimicrobial agents and chemotherapy2003
Mutations in topoisomerase genes of fluoroquinolone-resistant salmonellae in Hong Kong.
Article in Antimicrobial agents and chemotherapy, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 155 citations in OpenAlex.
- Systematic review: genotypic and phenotypic resistance of fluoroquinolone-resistantFrontiers in veterinary science · 2025Pooled it
- Use of transcriptomics and genomics to assess the effect of disinfectant exposure on the survival and resistance ofFrontiers in microbiology · 2024Article
- Whole-genome sequencing and phylogenetic analysis capture the emergence of a multi-drug resistantFrontiers in microbiology · 2023Article
- Antimicrobial resistance ofFrontiers in microbiology · 2022Article
- Genotypic Diversity of Ciprofloxacin Nonsusceptibility and Its Relationship with Minimum Inhibitory Concentrations in NontyphoidalAntibiotics (Basel, Switzerland) · 2021Article
- Phylogenomics and antimicrobial resistance ofMicrobial genomics · 2021Article
- Whole-Genome Sequencing Reveals the Presence of theAntibiotics (Basel, Switzerland) · 2021Article
- The molecular basis of extensively drug-resistant Salmonella Typhi isolates from pediatric septicemia patients.PloS one · 2021Article
- Contribution of Different Mechanisms to Ciprofloxacin Resistance inFrontiers in microbiology · 2021Article
- Antimicrobial Resistance Glides in the Sky-Free-Living Birds as a Reservoir of ResistantFrontiers in microbiology · 2021Article
- Analysis of existence of multidrug-resistant H58 gene inNew microbes and new infections · 2020Article
- Personalized Medicine for Antibiotics: The Role of Nanobiosensors in Therapeutic Drug Monitoring.Journal of personalized medicine · 2020Review
- The phenotypic and molecular characteristics of antimicrobial resistance of Salmonella enterica subsp. enterica serovar Typhimurium in Henan Province, China.BMC infectious diseases · 2020Article
- Epidemiological Study on Prevalence, Serovar Diversity, Multidrug Resistance, and CTX-M-Type Extended-Spectrum β-Lactamases ofAntimicrobial agents and chemotherapy · 2020Article
- Five ClosedMicrobiology resource announcements · 2020Article
- Genes and Proteomes Associated With Increased Mutation Frequency and Multidrug Resistance of Naturally Occurring Mismatch Repair-DeficientFrontiers in microbiology · 2020Article
- Chromosomal and plasmid-mediated fluoroquinolone resistance in human Salmonella enterica infection in Ghana.BMC infectious diseases · 2019Article
- Salmonella enterica subsp.Applied and environmental microbiology · 2019Article
- Horizontal Transfer of Antimicrobial Resistance Determinants Among Enteric Pathogens Through Bacterial Conjugation.Current microbiology · 2019Article
- A Historical Review on Antibiotic Resistance of FoodborneFrontiers in microbiology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A total of 88 salmonella isolates (72 clinical isolates for which the ciprofloxacin MIC was >0.06 microg/ml, 15 isolates for which the ciprofloxacin MIC was < or =0.06 microg/ml, and Salmonella enterica serotype Typhimurium ATCC 13311) were studied for the presence of genetic alterations in four quinolone resistance genes, gyrA, gyrB, parC, and parE, by multiplex PCR amplimer conformation analysis. The genetic alterations were confirmed by direct nucleotide sequencing. A considerable number of strains had a mutation in parC, the first to be reported in salmonellae. Seven of the isolates sensitive to 0.06 micro g of ciprofloxacin per ml had a novel mutation at codon 57 of parC (Tyr57-->Ser) which was also found in 29 isolates for which ciprofloxacin MICs were >0.06 micro g/ml. Thirty-two isolates had a single gyrA mutation (Ser83-->Phe, Ser83-->Tyr, Asp87-->Asn, Asp87-->Tyr, or Asp87-->Gly), 34 had both a gyrA mutation and a parC mutation (29 isolates with a parC mutation of Tyr57-->Ser and 5 isolates with a parC mutation of Ser80-->Arg). Six isolates which were isolated recently (from 1998 to 2001) were resistant to 4 micro g of ciprofloxacin per ml. Two of these isolates had double gyrA mutations (Ser83-->Phe and Asp87-->Asn) and a parC mutation (Ser80-->Arg) (MICs, 8 to 32 microg/ml), and four of these isolates had double gyrA mutations (Ser83-->Phe and Asp87-->Gly), one parC mutation (Ser80-->Arg), and one parE mutation (Ser458-->Pro) (MICs, 16 to 64 micro g/ml). All six of these isolates and those with a Ser80-->Arg parC mutation were S. enterica serotype Typhimurium. One S. enterica serotype Typhi isolate harbored a single gyrA mutation (Ser83-->Phe), and an S. enterica serotype Paratyphi A isolate harbored a gyrA mutation (Ser83-->Tyr) and a parC mutation (Tyr57-->Ser); both of these isolates had decreased susceptibilities to the fluoroquinolones. The MICs of ciprofloxacin, levofloxacin, and sparfloxacin were in general the lowest of those of the six fluoroquinolones tested. Isolates with a single gyrA mutation were less resistant to fluoroquinolones than those with an additional parC mutation (Tyr57-->Ser or Ser80-->Arg), while those with double gyrA mutations were more resistant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.